They had that advantage, probably back then it was more of an identity crisis " are they a CE company or a hearing aid company" but i think they totally lost themselves thinking they were going to get bought out and trying to sell it off in 2018 and they sadly took there eye off the ball and lost that first mover advantage and new players launched with primarily a better looking product but one that did not do hearing as well as Nuheara did it, and they do hearing very well.
Really needs CEO from a hearing retailer to take over the helm mate. That way you have a serious player at the top who knows how to actually sell the product in a hearing retail otc envirnoment. That is the ultimate issue here, is that you have a very talented group of R&D people there with AD etc, with a reallygood premium end hearing product/software who dont know how and where to sell it.
If they fix that up with a CEO from the retail end of the hearing space, they may well get to the point where they can nail those 3k units a month and actually get some decent deals on the table and kick on.Time is not on there side anymore but there is still a short space of time for them to tun it around.
- Forums
- ASX - By Stock
- NUH
- Ann: December 2023 Quarterly Activities Report
Ann: December 2023 Quarterly Activities Report, page-41
Featured News
Add NUH (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.91M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
NUH (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
SPONSORED BY The Market Online